The other selective antagonist tested in this study, C108297, also provides modest attenuation in hyperglycemia and peripheral insulin resistance and no changes to insulin response in vivo or β-cell function in this ROD model despite increased ex vivo β-cell response. This evidence concerns the gene INS and Hyperglycemia.